ArticleJournal of psychopharmacology (Oxford, England)2024
A semi-naturalistic open-label study examining the effect of prescribed medical cannabis use on simulated driving performance.
Article in Journal of psychopharmacology (Oxford, England), 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
8 citing papers in PubMed, 12 citations in OpenAlex.
- Driving performance and ocular activity following acute administration of 10 mg methylphenidate: A randomised, double-blind, placebo-controlled study.Journal of psychopharmacology (Oxford, England) · 2024Trial
- Beyond symptom change: a qualitative descriptive study of reported quality of life experiences among adults prescribed medicinal cannabis for anxiety disorders.International journal of clinical pharmacy · 2026Article
- The effects of orally ingested Delta-9-Tetrahydrocannabinol on drivers' hazard perception and risk-taking behaviours: A within-subjects study of medicinal cannabis users.Psychopharmacology · 2026Article
- Edible cannabis use on simulated driving performance.Traffic injury prevention · 2026Article
- Acute and chronic effects of medicinal cannabis use on anxiety and depression in a prospective cohort of patients new to cannabis.Journal of affective disorders · 2025Observational
- Impact of naturalistic cannabis use on lateral control and speed: A driving simulator study.Traffic injury prevention · 2025Article
- The driving-related attitudes, beliefs and behaviours of cannabis users in the Australian Capital Territory following decriminalisation.Drug and alcohol review · 2025Article
- Attitudes toward driving after cannabis use: a systematic review.Journal of cannabis research · 2024Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundDespite increasing medical cannabis use, research has yet to establish whether and to what extent products containing delta-9-tetrahydrocannabinol (THC) impact driving performance among patients. Stable doses of prescribed cannabinoid products during long-term treatment may alleviate clinical symptoms affecting cognitive and psychomotor performance.
aimTo examine the effects of open-label prescribed medical cannabis use on simulated driving performance among patients.
methodsIn a semi-naturalistic laboratory study, 40 adults (55% male) aged between 23 and 80 years, consumed their own prescribed medical cannabis product. Driving performance outcomes including standard deviation of lateral position (SDLP), the standard deviation of speed (SDS), mean speed and steering variability were evaluated using the Forum8 driving simulator at baseline (pre-dosing), 2.5 h and 5 -h (post-dosing). Perceived driving effort (PDE) was self-reported after each drive. Oral fluid and whole blood samples were collected at multiple timepoints and analysed for THC via liquid chromatography-mass spectrometry.
resultsA significant main effect of time was observed for mean speed (p = 0.014) and PDE (p = 0.020), with patients displaying modest stabilisation of vehicle control, increased adherence to speed limits and reductions in PDE post-dosing, relative to baseline. SDLP (p = 0.015) and PDE (p = 0.043) were elevated for those who consumed oil relative to flower-based products. Detectable THC concentrations were observed in oral fluid at 6-h post-dosing (range = 0-24 ng/mL).
conclusionsThis semi-naturalistic study suggests that the consumption of medical cannabis containing THC (1.13-39.18 mg/dose) has a negligible impact on driving performance when used as prescribed.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.